Selected Publications
Get a full list of publications in PubMed by clicking on this link.
Walter S, Jumpertz T, Hüttenrauch M, Ogorek I, Gerber H, Storck SE, Zampar S, Dimitrov M, Lehmann S, Lepka K, Berndt C, Wiltfang J, Becker-Pauly C, Beher D, Pietrzik CU, Fraering PC, Wirths O, Weggen S (2019). The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. Acta Neuropathol. 2019 Feb;137(2):239-257. PubMed
Goel P, Jumpertz T, Tichá A, Ogorek I, Mikles DC, Hubalek M, Pietrzik CU, Strisovsky K, Schmidt B, Weggen S (2018). Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors. Bioorg Med Chem Lett. 2018 May 1;28(8):1417-1422. PubMed
Goel P, Jumpertz T, Mikles DC, Tichá A, Nguyen MTN, Verhelst S, Hubalek M, Johnson DC, Bachovchin DA, Ogorek I, Pietrzik CU, Strisovsky K, Schmidt B, Weggen S (2017). Discovery and Biological Evaluation of Potent and Selective N-Methylene Saccharin-Derived Inhibitors for Rhomboid Intramembrane Proteases. Biochemistry. 2017 Dec 26;56(51):6713-6725. PubMed
Wirths O, Walter S, Kraus I, Klafki HW, Stazi M, Oberstein TJ, Ghiso J, Wiltfang J, Bayer TA, Weggen S (2017). N-truncated Aβ4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. Alzheimers Res Ther. 2017 Oct 4;9(1):80. PubMed
Storck SE, Meister S, Nahrath J, Meißner JN, Schubert N, Di Spiezio A, Baches S, Vandenbroucke RE, Bouter Y, Prikulis I, Korth C, Weggen S, Heimann A, Schwaninger M, Bayer TA, Pietrzik CU (2016). Endothelial LRP1 transports amyloid-ß1-42 across the blood-brain barrier. J Clin Invest. 2016 Jan 4;126(1):123-36. PubMed
Zettl H, Ness J, Hähnke V, Beher D, Jumpertz T, Saric A, Baumann K, Pietrzik CU, Bulic B, Schneider G, Weggen S (2012). Discovery of gamma-secretase modulators with a novel activity profile by text-based virtual screening. ACS Chemical Biology; 7:1488-95. PubMed
Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, Bulic B, Weggen S (2012). Presenilin is the molecular target of acidic gamma-secretase modulators in living cells. PLoS ONE; 7:e30484. PubMed
Hahn S, Brüning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik C, Bulic B, Weggen S (2011) Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure. Journal of Neurochemistry; 116:385-95. PubMed
Hieke M, Ness J, Steri R, Dittrich M, Greiner C, Werz O, Baumann K, Schubert-Zsilavecz M, Weggen S, Zettl H (2010) Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity. Journal of Medicinal Chemistry; 53:4691-700. PubMed
Richter L, Munter LM, Ness J, Hildebrand PW, Dasari M, Unterreitmeier S, Bulic B, Beyermann M, Gust R, Reif B, Weggen S, Langosch D, Multhaup G (2010) Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proceedings of the National Academy of Sciences of the United States of America; 107:14597-602. PubMed
Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TV, Esselmann H, Paul S, Schubenel R, Torpey JW, Pietrzik CU, Golde TE, Wiltfang J, Baumann KH, Koo EH, Weggen S (2008) Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. Journal of Biological Chemistry; 283:17049-54. PubMed
Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann KH, and Weggen S (2007) Insensitivity to Abeta42-lowering non-steroidal anti-inflammatory drugs (NSAIDs) and gamma-secretase inhibitors is common among aggressive presenilin-1 (PS1) mutations. Journal of Biological Chemistry; 282:24504-13. PubMed
Leuchtenberger S, Kummer MP, Kukar T, Czirr E, Teusch N, Sagi SA, Berdeaux R,Pietrzik CU, Ladd TB, Golde TE, Koo EH, Weggen S (2006) Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42. J Neurochem; 96:355-65. PubMed
Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE (2005) Diverse compounds mimic Alzheimer’s disease causing mutations by augmenting Abeta42 production. Nature Medicine; 11:545-50. PubMed
Weggen S, Eriksen J, Sagi S, Pietrzik CU Golde TE, Koo EH (2003) Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage in the amyloid precursor protein and ErbB-4 and signaling through the APP intracellular domain. Journal of Biological Chemistry; 278:30748-54. PubMed
Weggen S, Eriksen J, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH (2003) Evidence that nonsteroidal anti-inflammatory drugs decrease Abeta42 production by direct modulation gamma-secretase activity. Journal of Biological Chemistry; 278:31831-7. PubMed
Eriksen J, Sagi S, Monnier TE, Weggen S, McClendon DC, Ozols V, Jessing KW, Zavitz KH, Koo EH, Golde TE (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. Journal of Clinical Investigation; 112:440-9. PubMed
Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH (2002) The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in amyloid precursor protein processing. EMBO Journal; 21:5691-5700. PubMed
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, and Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature; 414:212-6. PubMed